Dyadic International Inc. ((DYAI)) has held its Q3 earnings call. Read on for the main highlights of the call.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
In a recent earnings call, Dyadic International Inc. showcased both achievements and challenges, painting a picture of cautious optimism. The company has made notable strides with its first commercial bulk sale and strategic partnerships, signaling positive momentum. However, a decline in revenue and an increased net loss underscore the financial obstacles it faces. Overall, the sentiment is one of cautious optimism, with strong strategic positioning but immediate financial hurdles to overcome.
First Commercial Bulk Sale
Dyadic International marked a significant milestone by achieving its first commercial bulk sale of a Dyadic-produced protein. This achievement signifies a pivotal transition from a platform-centric R&D organization to a commercially focused biotechnology company, highlighting the company’s shift towards commercial growth.
Rebranding and Website Relaunch
The company has rebranded itself as Dyadic Applied Biosolutions and launched a redesigned corporate website. This move is aimed at enhancing commercial engagement and reflects the company’s commitment to expanding its market presence.
CRISPR Cas9 Gene Editing License
Dyadic has secured a license for CRISPR Cas9 gene editing capabilities, which will enhance strain optimization and productivity. This development supports the company’s commercialization efforts and aims to improve profitability through advanced genetic capabilities.
Milestone Payments from ProLiant
The company received a total of $1.5 million in milestone payments from ProLiant, including a third payment of $500,000 in October. This progress in the recombinant human albumin program underscores Dyadic’s advancements in its biopharmaceutical initiatives.
Partnership with Intralink
Dyadic has partnered with Intralink to accelerate market penetration in Japan and South Korea. This strategic partnership is expected to efficiently expand the company’s global market reach, particularly in the Asian markets.
Decrease in Total Revenue
For the third quarter of 2025, Dyadic reported a decrease in total revenue to $1,165,000 from $1,958,000 in the same period a year ago. This decline was driven by decreases in R&D and license and milestone revenue, highlighting the financial challenges the company is facing.
Increase in Loss from Operations
The company’s loss from operations increased significantly to $1,925,000 compared to $203,000 in the same period a year ago. This increase reflects higher general and administrative (G&A) and R&D expenses, indicating the financial pressures on the company.
Net Loss Increase
Dyadic’s net loss for Q3 2025 increased to $1,976,000 or $0.06 per share, compared to $203,000 or $0.01 per share a year ago. This increase in net loss highlights the financial hurdles the company needs to address moving forward.
Forward-Looking Guidance
During the earnings call, Dyadic provided guidance on its strategic directions and key metrics. The company emphasized its transition to Dyadic Applied Biosolutions, focusing on commercial growth with the first bulk sale of a Dyadic-produced protein. Despite a decrease in total revenue for Q3 2025, Dyadic is optimistic about additional product opportunities emerging in 2025 and accelerating in 2026. The company closed a public offering raising approximately $4.9 million and held $10.4 million in cash and equivalents as of September 30, 2025. Dyadic remains focused on life sciences and food nutrition segments, expecting growth from its recombinant protein platforms and continued advancement in its biopharmaceutical programs supported by non-dilutive funding.
In conclusion, Dyadic International Inc.’s earnings call highlighted a mix of strategic advancements and financial challenges. The company’s cautious optimism is reflected in its strategic positioning and partnerships, despite immediate financial hurdles. Investors and stakeholders will be keenly watching how Dyadic navigates these challenges while capitalizing on its growth opportunities.